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Developing countries shoulder most of the burden of diabetes and tuberculosis. These diseases often coexist.
Suboptimal control of diabetes predisposes the patient to tuberculosis, and is one of the common causes of poor
response to anti-tubercular treatment. Tuberculosis also affects diabetes by causing hyperglycemia and causing
impaired glucose tolerance. Impaired glucose tolerance is one of the major risk factors for developing diabetes. The
drugs used to treat tuberculosis (especially rifampicin and isoniazid) interact with oral anti-diabetic drugs and may
lead to suboptimal glycemic control. Similarly some of the newer oral anti-diabetic drugs may interact with
anti-tuberculosis drugs and lower their efficacy. Therefore diabetes and tuberculosis interact with each other at
multiple levels – each exacerbating the other. Management of patients with concomitant tuberculosis and diabetes
differs from that of either disease alone. This article reviews the association between diabetes and tuberculosis and
suggests appropriate management for these conditions.
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Tuberculosis (TB) is one of the most common infectious
diseases worldwide. For several decades, the research
community has been working for an effective preventive
strategy for TB. It is clear that although the current pre-
ventive efforts against the spread of TB have lowered its
incidence, the problem is far from over. Therefore the
focus of research has now shifted to the previously
untargeted risk factors involved in the spread of TB.
One such factor is diabetes mellitus (DM). It is well
known that DM impairs the immunity of patients and
therefore is an independent risk factor for infections
such as TB.
Reports on the association between DM and TB date
back to 1000 A.D.; when Avicenna noted that ‘phthisis’,
(Greek: tuberculosis), often complicated diabetes and
that the presence of diabetes resulted in an increased
risk of developing TB [1]. Another description is seen in
the works of Yugimahamuni, a traditional Indian saint.
He described the association of DM and TB by a com-
bination of symptoms called ‘meganoikal’. These* Correspondence: asfand92@gmail.com
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ence, respiratory symptoms and unconsciousness [2].
Each disease is thought to exacerbate and worsen the
outcome for the other. TB is a specific morbidity often
associated with DM and is therefore aptly described as a
complication of DM [3]. People with diabetes are more
susceptible to infections and suffer from relatively severe
illness due to their immuno-compromised status [4],
with reactivation of older foci of TB rather than through
fresh contact [5], and often exhibit lower lobe involve-
ment more commonly than in non-diabetics. Various
studies have shown that 5-30% of patients with TB have
DM as well [6].Diabetes as a risk factor for tuberculosis
The incidence of DM is increasing worldwide, especially
in developing countries where TB is most prevalent [7].
Therefore the convergence of these two epidemics is
most likely to occur in the places with the least amount
of healthcare resources. Diabetes is an independent risk
factor for all lower respiratory tract infections [8]. A re-
view [9] found 9 studies in which diabetes was estimated
to increase the risk of TB from 1.5 to 7.8 fold. Even
though TB is more strongly associated with other im-
mune deficiency diseases such as HIV, as the number ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with other immunocompromised states, it make
DM a more significant risk factor for TB at the popula-
tion level [10]. A meta-analysis demonstrated that dia-
betes was associated with a relative risk of 3.11 of
contracting TB [11]. An American study has found that
multi-drug resistant TB is associated with DM with an
odds ratio of 2.1 [12].
Even though type 2 DM is more prevalent, type 1 DM
carries a stronger risk of contracting TB [13]. Other risk
factors for developing TB in people with type 1 DM in-
clude a low body weight, young age, and poor glycemic
control [13].
It is not clear whether DM can affect the presentation
of TB. Clinical studies have shown ambiguous results.
However patients with concomitant TB and DM may
have a higher rate of fever and hemoptysis and atypical
radiological images. Some studies reported a higher,
while others reported a lower, frequency of cavities in
the lungs of people with diabetes as compared to non-
diabetics with TB [14].
Some studies have also reported a negative effect of
DM on the treatment efficacy and prognosis of TB [14].
However, results are conflicting and there is no clear evi-
dence that DM affects the efficacy of treatment of TB.
DM also alters the pharmacokinetics of several anti-TB
drugs. Since the efficacy of most anti-TB drugs depends
on their plasma concentration, it may explain the nega-
tive effect of DM on the treatment of TB [7]. The altered
plasma levels may be due to differences in absorption,
distribution, metabolism and/or excretion in diabetics.
Lower plasma levels of anti-TB drugs are associated with
resistance to these drugs which may complicate the
course of treatment of TB in people with diabetes [15].Tuberculosis as a risk factor for diabetes
The relationship between DM and TB is bi-directional.
Tuberculosis may lead to the development of new dia-
betes cases [16,17]. Studies have shown a high preva-
lence of diabetes,as well as impaired glucose tolerance,
in patients with tuberculosis [18]. Impaired glucose
tolerance is a significant risk factor for developing DM.
In most of these cases, the impaired glucose tolerance
reverts back to normal after successful treatment for
TB, however the increased risk of developing DM
persists [19].
Active tuberculosis should be a differential diagnosis
in patients with enlarged pancreas. TB is a known cause
of pancreatitis [20] and tuberculous pancreatitis might
reveal itself only after the development of diabetes. Even
though a part of the hyperglycemia associated with TB
may be attributed to the severe stress associated with
the infection itself, however the major factor in thisprocess is hypofunction of the pancreas [19,20]. The role
of drug interactions is discussed later.
On the other hand, it has been shown that testing for
DM in previously undiagnosed people before the appro-
priate treatment for TB may lead to an over-diagnosis of
DM [20]. TB can lead to an infection-related hypergly-
cemia which may mimic DM. The hyperglycemia asso-
ciated with TB often aggravates the glycemic control of
diabetics and thus warrants adjustment in the dose of in-
sulin [19]. The dose adjustment should be repeated after
the patient has been successfully treated for TB.
Etiology of the association
Diabetes is associated with a decrease in cellular immun-
ity. There are fewer T lymphocytes and a decreased neu-
trophil count in diabetics. A reduced T-helper1 (Th1)
cytokine response level, TNF alpha production, and IL-1
beta and IL-6 production is also seen amongst people
with concomitant diabetes and TB as compared to non-
diabetic individuals [21-23]. Th1 cytokines are vital in
the control and inhibition of mycobacterium tubercu-
losis bacilli. This decrease in T lymphocyte number and
function is primarily responsible for the susceptibility of
diabetics to TB. Macrophage function is also inhibited in
individuals with diabetes, with an impairment of the
production of reactive oxygen species, and phagocytic
and chemotactic function. Hyperglycemia has a direct
depressive effect on the respiratory burst. A combination
of these dysfunctional processes contributes to an
increased risk of TB in diabetes [21,22].
It is worthwhile to mention that both these diseases
may simulate the symptoms of the other. Such symp-
toms that are common to both include lethargy, fatigue,
weight loss, fever and loss of appetite. It is not unheard
of for people with diabetes to present to the doctor with
complaints of worsening of blood glucose control only
to find out later that they have TB.
Management of diabetes
Management of DM in TB should be aggressive. An op-
timal glycemic control results in a better patient out-
come; therefore vigorous efforts should be made to
achieve such control. Insulin therapy should be initiated
at the outset, using basal bolus regime or premixed insu-
lin. The American Association of Clinical Endocrinolo-
gists recommends the use of modern insulins or insulin
analogues, as they are more predictable in action and
cause less hypoglycemia. The use of traditional human
insulins is discouraged [24].
Insulin requirements are high to begin with but fall
after a few weeks once glucotoxicity is corrected and in-
fection is controlled. Insulin requirements may rise again
as appetite returns to normal and caloric intake increases.
Sick patients should be tested for ketonuria [25]. Rapid
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need for admission in patients with ketonuria [26] and
are useful for critically ill patients as well [27].
An average patient will need 1.0 U/kg/day of insulin ini-
tially, divided as 60% bolus and 40% basal insulin. In a few
weeks, the requirement will come down to 0.5 U/kg/day,
and may be met by two or three equal doses of premixed
aspart/lispro [28]. In patients with co-existing peripheral
neuropathy due to diabetes, it is mandatory to give the pa-
tient pyridoxine if isoniazid is to be used.
The rationale for exogenous insulin therapy in patients
with type 2 diabetes and active tuberculosis is given
below [29]:
1) Severe tuberculosis infection
2) Loss of tissue and function of pancreasa) pancreatic endocrine deficiency
b) tuberculous pancreatitis
3) a) Requirement of high calorie, high protein diet
b) Need for anabolic effect
4) Interactions of antituberculosis drugs with oral
antidiabetic drugs
5) Associated hepatic disease prevents use of oral
antidiabetic drugs
Oral hypoglycemic agents are contraindicated in se-
vere tuberculosis but may be used with caution once the
disease has settled.
Rifampicin is a potent hepatic enzyme-inducer. It
accelerates the metabolism of several oral hypoglycemic
agents, especially sulphonylureas and biguanides, and
lowers their plasma levels. Therefore it may cause hyper-
glycemia in diabetic patients using these drugs. In non-
diabetics, it augments the intestinal absorption of
glucose and may simulate the symptoms of diabetes [30].
Isoniazid, in contrast to rifampicin, inhibits the metab-
olism of oral hypoglycaemic agents and may lead to an
increase in the plasma levels of these drugs. Its main
interaction is with sulphonylureas, the action of which it
antagonizes and worsens the glycemic control of dia-
betics on this medication. It also impairs the release and
action of insulin leading to hyperglycemia even in non-
diabetics [31]. Therefore the dosage of insulin should
be adjusted while adding and removing these drugs
from the patients’ prescriptions. Dipetidyl protease inhi-
bitors (the gliptins), a comparatively newer class of
hypoglycemic agents, have a theoretical possibility of re-
ducing immunocompetence because of their mechanism
of action [32]. This effect could possibly worsen the out-
come of patients with TB.
Conclusions
Diabetes and tuberculosis should be treated aggressively
with insulin. In case a person with diabetes and activetuberculosis is poorly controlled on oral hypoglycemic
agents, it is necessary to switch to insulin. The choice of
insulin regime should be based on efficacy, safety, toler-
ability and convenience.
South Asia is known as the diabetes capital and the tu-
berculosis capital of the world. Both diseases are linked
with each other, and need to be treated together for op-
timal outcome. A concerted effort on our part can
change our designation to the Diabetes CARE capital
and Tuberculosis CARE capital of the world.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AKN was involved in searching the literature and helped in drafting the
article. SK wrote the first draft of the article and edited the article throughout
all stages. Both authors read and approved the final manuscript.
Acknowledgements
There are no acknowledgements to be made.
Author details
1Shifa College of Medicine, H-8/4 Islamabad, Pakistan. 2Bharti Hospital and
B.R.I.D.E, Karnal, India.
Received: 22 August 2012 Accepted: 18 December 2012
Published: 20 December 2012
References
1. Morton R: Phthisiolgia: or a treatise of consumptions. London: Smith and
Walford; 1694.
2. Rajalakshmi S, Veluchamy G: Yugi's pramegam and diabetes mellitus: an
analogue. Bull Indian Inst Hist Med Hyderabad. 1999, 29(1):83–7.
3. West KM: Epidemiology of diabetes and its vascular lesions. New York:
Elsevier; 1978:351.
4. Tattersall RB, Gale EAM: Infections. In Diabetes, clinical management. Edited
by Tattersall RB, Gale EAM. Edinburgh: Churchill Livingstone; 1990:358–364.
5. Wilson RM: Infection and diabetes mellitus. In Textbook of diabetes.
Edited by Pickup JC, Williams G. Oxford: Blackwell Scientific Publication;
1991:813–9.
6. Ruslami R, Aarnoutse RE, Alisjahbana B, Van Der Ven AJAM, Van Crevel R:
Implications of the global increase of diabetes for tuberculosis control
and patient care. Trop Med & Int Health 2010, 15:1289–1299.
7. Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan
RHH, et al: Exposure to rifampicin is strongly reduced in patients with
tuberculosis and type 2 diabetes. Clin Infect Dis 2006, 43(7):848–854.
8. Winterbauer R, Bedon G, Ball W: Recurrent Pneumonia: Predisposing
illness and clinical pattern of 158 patients. Ann Intern Med 1969, 70:689.
9. Stevenson CR, Critchley JA, Forouhi NG, Roglic G, Williams BG, Dye C, et al:
Diabetes and the risk of tuberculosis: a neglected threat to public
health? Chronic Illn 2007, 3:228–45.
10. Restrepo BI: Convergence of the tuberculosis and diabetes epidemics:
Renewal of old acquaintances. Clin Infect Dis 2007, 45(4):436–438.
11. Jeon C, Murray M: Diabetes mellitus increases the risk of active
tuberculosis: A systematic review of 13 observational studies. PLoS Med
2008, 5:e152.
12. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purva AM, Ahmad Y, Ottenhoff TH,
et al: The effect of type 2 diabetes mellitus on the presentation and
treatment response of pulmonary tuberculosis. Clin Infect Dis 2007,
45:428–35.
13. Swai AB, McLarty DG, Mugusi F: Tuberculosis in diabetic patients in
Tanzania. Trop Doct. 1990, 20(4):147–50.
14. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y,
Ottenhoff THM, et al: The effect of diabetes mellitus on the presentation
and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007,
45(4):428–435.
Niazi and Kalra Journal of Diabetes & Metabolic Disorders 2012, 11:28 Page 4 of 4
http://www.jdmdonline.com/content/11/1/2815. Englebach K: Passagerer diabetes mellitus bei 2 Tuberkulosekranken
[Transitory diabetes mellitus in two tuberculotics.]. J Beitr Klin Tuberk
Spezif Tuberkuloseforsch 1954, 110:470–3.
16. Nichols GP: Diabetes among young tuberculous patients; a review of the
association of the two diseases. Am Rev Tuberc 1957, 76:1016–30.
17. Mugusi F, Swai A, Alberti K, Melarty G: Increased prevalence of diabetes
mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle
1990, 71:271–6.
18. Jeon CY, Harries AD, Baker MA, Hart JE, Kapur A, Lönnroth K, et al:
Bi-directional screening for tuberculosis and diabetes: a systematic
review. Trop Med Int Health 2010, 15:1300–1314.
19. Guptan A, Shah A: Tuberculosis and diabetes: an appraisal. Ind J Tub 2000,
47(3):2–8.
20. Geevarghese PJ: Pancreatic diabetes. Popular Prakashan: Bombay;
1967:26–28.
21. Geerlings SC, Hopelman AI: Immune dysfunction in patients with diabetes
mellitus (DM). FEMS Immunol Med Microbiol 1999, 26:259–65.
22. Tsukaguchi K, Yoneda T, Yoshikawa M: Case study of interleukin-1 beta,
tumor necrosis factor alpha and interleukin-6 production by peripheral
blood monocytes in patients with diabetes mellitus complicated by
pulmonary tuberculosis. Kekkaku 1992, 67:755–60.
23. Sidibe EH, Sankale M: Diabetes and pulmonary tuberculosis:
epidemiology, pathophysiology and symptomatology. J French Stud Res
Health 2007, 17(1):29–32.
24. Rodbard HW, Jelleinger PS, Davidson JA, et al: Statement by an AACE/ACE
Consensus Panel on type 2 diabetes mellitus An algorithm for glycemic
control. Endocrine Practice 2009, 15(6):540–559.
25. Kalra S, Kalra B, Sharma A: Ketonuria and ketonemia in type 2 diabetes
mellitus patients attending an Indian endocrine clinic. Ind J Endocr &
Metab 2007, 11(3–4):7–10.
26. Kalra S, Kalra B, Nanda G: OPD management of ketosis in pregnancy:
aspart vs. regular insulin. Diabetic Med 2006, 23(4):504.
27. Kalra S: Walking the tightrope in critical care: role of rapid-acting
analogue insulin. In Medicine Update 2009 (Vol 19 Part I). 19th edition.
Edited by Agarwal AK. New Delh: Jay Pee Bros; 2009:388–394.
28. Kalra S, Kalra B, Sharma A, Chhabra B: Dosage frequency of premixed
aspart insulin: clinical correlates of three-dose. Diabetes 2008, 57(1):570.
29. Rao PV: Persons with type 2 diabetes and co-morbid active tuberculosis
should be treated with insulin. Int J Diab Dev Countries 1999, 19:79–86.
30. Atkin SL, Masson EA, Bodmer CW, Walker BA, White MC: Increased insulin
requirement in a patient with Type 1 diabetes on rifampicin [letter].
Diabet Med 1993, 10:392.
31. Lebovitz HE: Oral hypoglycemic agents. Ellenberg and Rifkins’s diabetes
mellitus, theory and practice. 4th ed. New York: Elsevier: Rifkin H, Porte Jr D,
eds; 1990:554–574.
32. Madsbad S: Treatment of type 2 diabetes with incretin-based therapies.
Lancet 2009, 373(9662):438–439.
doi:10.1186/2251-6581-11-28
Cite this article as: Niazi and Kalra: Diabetes and tuberculosis: a review
of the role of optimal glycemic control. Journal of Diabetes & Metabolic
Disorders 2012 11:28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
